Eli Lilly Lowers 2024 Revenue Forecast Due to Slower Weight-Loss Drug Growth

The pharmaceutical giant adjusts expectations for Mounjaro and Zepbound sales while planning increased production capacity for 2025.

Eli Lilly revised its Q4 2024 revenue projection to $13.5 billion, falling short of analysts' expectations of $13.94 billion.
Sales of Mounjaro and Zepbound were below forecasts, with $3.5 billion and $1.9 billion in revenue, respectively, attributed to slower-than-anticipated market growth and lower year-end inventory levels.
The company expects 2025 revenue to range between $58 billion and $61 billion, exceeding Wall Street's forecast of $58.52 billion.
Eli Lilly has resolved the U.S. shortage of tirzepatide, the active ingredient in Mounjaro and Zepbound, and plans a 60% increase in production capacity for the first half of 2025 compared to the same period in 2024.
The company is also developing an experimental weight-loss pill, orforglipron, which CEO David Ricks anticipates could receive regulatory approval as early as 2026, potentially offering a more convenient alternative to injectable treatments.